高级搜索

乳腺癌恶性胸腔积液的临床特征及预后因素分析

邵彬, 余靖, 邸立军, 宋国红, 朱步东, 车利, 贾军, 姜晗昉, 祝毓琳, 梁旭, 张洁, 王超颖, 严颖, 吕敏, 林晓琳, 黄晓蕾, 尤渺宁, 王小利, 周心娜, 任军

邵彬, 余靖, 邸立军, 宋国红, 朱步东, 车利, 贾军, 姜晗昉, 祝毓琳, 梁旭, 张洁, 王超颖, 严颖, 吕敏, 林晓琳, 黄晓蕾, 尤渺宁, 王小利, 周心娜, 任军. 乳腺癌恶性胸腔积液的临床特征及预后因素分析[J]. 肿瘤防治研究, 2013, 40(04): 381-387. DOI: 10.3971/j.issn.1000-8578.2013.04.015
引用本文: 邵彬, 余靖, 邸立军, 宋国红, 朱步东, 车利, 贾军, 姜晗昉, 祝毓琳, 梁旭, 张洁, 王超颖, 严颖, 吕敏, 林晓琳, 黄晓蕾, 尤渺宁, 王小利, 周心娜, 任军. 乳腺癌恶性胸腔积液的临床特征及预后因素分析[J]. 肿瘤防治研究, 2013, 40(04): 381-387. DOI: 10.3971/j.issn.1000-8578.2013.04.015
shu
SHAO Bin, YU Jing, DI Lijun, SONG Guohong, ZHU Budong, CHE Li, JIA Jun, JIANG Hanfang, ZHU Yulin, LIANG Xu, ZHANG Jie, WANG Chaoying, YAN Ying, LV Min, LIN Xiaolin, HUANG Xiaolei, YOU Miaoning, WANG Xiaoli, ZHOU Xinna, REN Jun. Clinical Characteristics and Prognostic Factors in Breast Cancer with Malignant Pleural Effusion[J]. Cancer Research on Prevention and Treatment, 2013, 40(04): 381-387. DOI: 10.3971/j.issn.1000-8578.2013.04.015
Citation: SHAO Bin, YU Jing, DI Lijun, SONG Guohong, ZHU Budong, CHE Li, JIA Jun, JIANG Hanfang, ZHU Yulin, LIANG Xu, ZHANG Jie, WANG Chaoying, YAN Ying, LV Min, LIN Xiaolin, HUANG Xiaolei, YOU Miaoning, WANG Xiaoli, ZHOU Xinna, REN Jun. Clinical Characteristics and Prognostic Factors in Breast Cancer with Malignant Pleural Effusion[J]. Cancer Research on Prevention and Treatment, 2013, 40(04): 381-387. DOI: 10.3971/j.issn.1000-8578.2013.04.015
shu

乳腺癌恶性胸腔积液的临床特征及预后因素分析

  • 100142 北京，北京大学临床肿瘤学院,北京肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科恶性肿瘤发病机制及转化研究教育部重点实验室

详细信息
    作者简介:

    邵彬（1979-），男，硕士，主治医师，主要从事晚期乳腺癌的临床治疗与科研工作

    通讯作者:

    任军，E-mail:renjun9688@yahoo.com

  • 中图分类号: R737.9

Clinical Characteristics and Prognostic Factors in Breast Cancer with Malignant Pleural Effusion

  • Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital & Institute, Peking University School of Oncology, Beijing 100142, China

摘要

    摘要
  • 摘要: 目的 研究有症状乳腺癌恶性胸腔积液患者的临床特征及影响疗效的相关因素。 方法 回顾性总结分析了2008年11月至2010年12月我科收治的36例有症状胸腔积液乳腺癌患者的一般临床资料[年龄、东部肿瘤协作组（ECOG）、手术病理分期、手术后无病生存期（DFS）、胸腔积液是否为初次复发部位、是否复发后一线化疗、是否伴有其他积液、是否双侧胸腔积液]，胸腔积液的情况[是否血性胸腔积液、胸水细胞数、胸水单核细胞数、乳酸脱氢酶（LDH）、癌胚抗原（CEA）、CA153、CA125、蛋白、胸水量]及胸腔积液的治疗情况（胸腔局部治疗方式、胸腔局部化疗药物、是否使用IL-2）中各种因素对于胸腔积液疗效及控制时间的影响。 结果 患者手术至出现胸腔积液的中位时间44月（0~180月）。手术至出现胸腔积液的时间>44月有效率显著高于手术后DFS≤44月者（P=0.046），分别为66.7%，33.3%；复发后一线化疗者有效率显著高于复发后二线及以上化疗者（P=0.044），分别为65.0%和31.3%；胸水单核细胞数>1×106/L的患者有效率显著高于胸水单核细胞数≤1×106/L（P=0.046）的患者，分别为66.7%，33.3%。胸腔积液中位控制时间为4月，胸腔积液LDH≤400 u/ml较LDH>400 u/ml的患者的胸腔积液控制时间显著延长（P=0.032），胸腔积液中位控制时间分别为6月和2月。 结论 胸腔积液是乳腺癌患者常见的临床表现，术后DFS时间长、复发后一线化疗及胸水单核细胞高者有效率高，胸腔积液LDH浓度高是胸水控制时间短的不良预后因素。

     

    Abstract: Objective To investigate the clinical characteristics and prognostic factors of the patients with breast cancer who had symptomatic malignant pleural effusion (MPE). Methods The data of 36 patients underwent pleurodesis for malignant pleural from Nov 2008 to Dec 2010 were collected. It included the patients' general clinical data (age, ECOG, surgical-pathological staging, postoperative DFS, the pleural effusion being the first recurrence,first-line chemotherapy, other effusion, and bilateral pleural effusion), details of pleural effusion (whether it was congestive pleural effusion, number of the effusion cells or not, number of monocytes, LDH, CEA, CA153, CA125, protein, and quantity of pleural effusion) and treatments of pleural effusion (local treatment, local chemotherapeutics, whether to use IL-2). The factors which influenced pleural effusion treatments and its time control under the above conditions were analyzed. Results The median time of the interval between surgery and the onset of MPE was 44 months(0-180 months). The patients with the interval time between surgery and onset of MPE longer than 44 months had higher response rate(66.7%) than those less than 44 months (33.3%)（P=0.046）.The patients receiving first line chemotherapy (65.0%) had higher response rate than those receiving more than first line chemotherapy (31.3%,P=0.044）.The mononuclear cell number in the pleural effusion influenced the response rate to a significant degree（P=0.046）. The median pleural effusion control time was 4 months.The patients with lactate dehydrogenase (LDH) concentration higher than 400 u/L(6 months) had longer median pleural effusion control time than those with LDH concentration lower than 400 u/L (2 months)(P=0.032). Conclusion Malignant pleural effusion was the common presentation for advanced breast cancer. The interval time between surgery and onset of MPE, first line chemotherapy and mononuclear cell number in the pleural effusion significantly affected the response rate.The LDH concentration in pleural effusion was a good predictor of pleural effusion control time.

     

    • HTML全文
    • 参考文献(26)
  • [1] Chen H, Brahmer J. Management of malignant pleural effusion[J].Curr Oncol Rep, 2008, 10(4): 287-93.
    [2] Apffelstaedt JP, Van Zyl JA, Muller AG. Breast cancer complicated by pleural effusion: patient characteristics and results of surgical management[J]. J Surg Oncol,1995, 58(3):173-5.
    [3] Banerjee AK, Willets I, Robertson JF, et al. Pleural effusion in breast cancer: a review of the Nottingham experience[J]. Eur J Surg Oncol,1994, 20(1):33-6.
    [4] Fentiman IS, Millis R, Sexton S, et al. Pleural effusion in breast cancer: a review of 105 cases[J]. Cancer,1981, 47(8):2087-92.
    [5] Musani AI. Treatment options for malignant pleural effusion[J]. Curr Opin Pulm Med,2009,15(4):380-7.
    [6] van den Toorn LM,Schaap E,Surmont VF, et al. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter[J]. Lung Cancer,2005,50(1):123-7.
    [7] Debeljak A, Kecelj P, Triller N, et al. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions[J]. J BUON, 2006,11(4):463-7.
    [8] Margaritora S, Cesario A, Vita ML, et al. Single versus multiple access video-assisted thoracic surgery in the treatment of malignant pleural effusion[J]. Eur J Cardiothorac Surg, 2007,32(2):397-8.
    [9] Stefani A, Natali P, Casali C, et al. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study[J]. Eur J Cardiothorac Surg, 2006,30(6):827-32.
    [10] Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review[J]. Eur J Cardiothorac Surg, 2006,29(5):829-38.
    [11] Ong KC, Indumathi V, Raghuram J, et al. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions[J]. Respirology, 2000,5(2):99-103.
    [12] Lynch T, Kalish L, Mentzer S,et al. Optimal therapy of malignant pleural effusions[J]. Int J Oncol, 1996,8(1):183-90.
    [13] Griffo S, Musumeci A, De Luca G, et al. Talc-induced interstitial pneumonitis with respiratory failure[J]. Anaesth Intensive Care, 2009,37(1):127-9.
    [14] Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study[J]. Lancet, 2007,369(9572):1535-9.
    [15] Yu J,Di LJ,Song GH,et al.Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer[J].Beijing Da Xue Xue Bao(Yi Xue Ban),2011,43(1):151-7. [余靖，邸立军，宋国红，等. 多西他赛联合塞替派与多西他赛联合卡培他滨治疗转移性乳腺癌的随机、对照临床研究[J]. 北京大学学报（医学版）,2011,43(1):151-7.]
    [16] Martinoni A, Cipolla CM, Cardinale D, et al. Long-term results of intrapericardial chemotherapeutic treatment of pericardial effusions with thiotepa[J]. Chest, 2004, 126(5):1412-6.
    [17] Luh KT, Yang PC, Kuo SH, et al. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial[J]. Cancer, 1992,69(3):674-9.
    [18] Nio Y, Nagami H, Tamura K, et al. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion[J]. Br J Cancer, 1999,80(5-6):775-85.
    [19] Dalbeth N, Lee YC. Lymphocytes in pleural disease[J]. Curr Opin Pulm Med, 2005, 11(4): 334-9.
    [20] Beyer M, Kochanek M,Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine[J]. Blood, 2005, 106(6): 2018-25.
    [21] Di LJ,Ren J,Song GH,et al.Treatment of malignant effusions with the injection of dendritic cells derived from autologous peripheral CD34+ stem cells[J]. Beijing Da Xue Xue Bao(Yi Xue Ban) ,2008,40(5):486-8. [邸立军,任军,宋国红,等. 自体外周血CD34+干细胞来源树突状细胞体外扩增治疗恶性体腔积液[J]. 北京大学学报（医学版）,2008,40(5):486-8.]
    [22] Alexandrakis M, Coulocheri S, Kyriakou D, et al.Diagnostic value of ferritin, haptoglobin, alpha 1-antitrypsin, lactate dehydrogenase and complement factors C3 and C4 in pleural effusion differentiation[J]. Respir Med, 1997,91(9):517-23.
    [23] Martínez-Moragón E, Aparicio J, Sanchis J, et al. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases[J]. Respiration, 1998, 65(2):108-13.
    [24] Light RW, Ball WC Jr. Lactate dehydrogenase isoenzymes in pleural effusions[J].Am Rev Respir Dis,1973,108(3):660-4.
    [25] Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions. An assessment of the prognostic values of physiologic, morphologic and quality of life measures of extent of disease[J]. Chest, 2000,117(1):73-8.
    [26] Singer TS, Sulkes A, Biran S. Pleural effusion in breast cancer:influence upon clinical course and survival[J]. Chemioterapia, 1986,5(1):66-9.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  2389
  • HTML全文浏览量:  19
  • PDF下载量:  967
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-06-14
  • 修回日期:  2012-10-16
  • 刊出日期:  2013-04-24

目录

摘要
HTML全文
    参考文献(26)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11622126 今日访问：29886

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭

    《肿瘤防治研究》杂志关于升级编辑出版系统的通知